Compare Incyte Corporation (INCY) vs Ishares Msci Thailand Etf (THD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Ishares Msci Thailand Etf — how do they compare? Incyte Corporation trades at $115.7 (market cap $23.11B), while Ishares Msci Thailand Etf trades at $73.43. Which is the better fit depends on your goals.
| INCY | THD | |
|---|---|---|
Market Cap | $23.11B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $118.52 | $75.05 |
52-Week Low | $67.38 | $55.83 |
Enterprise Value | $19.13B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
THD trades at $73.02, up 0.21% on the day, with a bullish technical outlook supported by moving averages and an upcoming dividend of $1.71 scheduled for June 2026. Recent news highlights its strong performance, with nearly 38% total returns over the past year, driven by exposure to AI hardware plays like Delta Electronics. The stock's momentum is reinforced by positive sentiment from financial media, though key financial ratios remain undisclosed in the provided data.
Outlook is cautiously optimistic due to technical strength and AI-driven growth potential, but risks include vulnerability to profit-taking and macroeconomic factors. Investors should monitor earnings reports for fundamental validation, as current data lacks detailed financial metrics. The stock faces competition and regional economic shifts, requiring careful assessment of future guidance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Ishares Msci Thailand Etf
THD is a country-specific ETF that tracks the performance of the Thai equity market. It provides broad exposure to Thailand's economy across sectors like electronics, energy, and financials, with top holdings such as Delta Electronics.
Read more on THD →
